WJWilliam Jeffcoate

William Jeffcoate

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


William Jeffcoate has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Controversies in Diagnosing and Managing Osteomyelitis of the Foot in Diabetes

    by William J. Jeffcoate, Benjamin A. Lipsky

    The optimal approach to diagnosing and managing osteomyelitis of the foot in diabetes is unclear. Diagnosis is based on clinical signs, supplemented


  • Off-Loading in Trials in Neuropathic Diabetic Foot Ulceration

    by William J. Jeffcoate, Frances L. Game, Patricia E. Price


  • Top Cited Papers

    Diabetic foot ulcers

    by William J Jeffcoate, Keith G Harding


  • Growth Hormone Therapy and its Relationship to Insulin Resistance, Glucose Intolerance and Diabetes Mellitus

    by William Jeffcoate

    It is widely recommended that consideration should be given to the therapeutic use of growth hormone (GH) in adults with GH deficiency, whether the condition is of childhood or adult onset. One reason for this recommendation is the possibility that such treatment may reduce the excess cardiovascular risk which is associated with hypopituitarism. This excess risk has been well documented, with mortality ratios of 1.7 to 2.2 being quoted in different studies, and may be a result of the insulin resistance which occurs in hypopituitarism. However, it has also been suggested that this insulin resistance may itself be the result of GH deficiency, especially as GH deficiency is accompanied by suggestive morphological features such as central adiposity. There is, however, no direct evidence that the increase in cardiovascular risk in hypopituitarism is the result of GH deficiency, and the only prospective study designed to examine the relationship failed to find a statistically significant correlation between the two. Since GH administration may also have an independent adverse effect on insulin sensitivity and could thus cause a theoretical worsening of cardiovascular risk, it is important to review the observed effects of GH administration on carbohydrate metabolism in practice. Interpretation of the literature is made difficult by many confounding factors, including differences in study duration, biochemical tools adopted, the use of selected populations and the dose-dependent effect of GH on synthesis of insulin-like growth factor-1. One of the most sensitive markers of a deterioration in insulin sensitivity is the serum insulin level. A rise in serum insulin (fasting, or post-glucose load) was reported in all studies in which it was measured. The majority of studies have also reported a rise in fasting blood glucose. A smaller proportion of reports noted an associated increase in postprandial glucose and in glycosylated haemoglobin (HbA1c) while a few reported new cases of either impaired glucose tolerance or frank diabetes mellitus. In general, however, the observed deterioration in insulin sensitivity was small and increases which occurred in blood glucose were small. Nevertheless, these data indicate that rather than lead to an improvement in insulin resistance in hypopituitarism, GH treatment may actually make it worse. As it is also known that even minor reductions in insulin sensitivity may be associated with a clinically significant increase in cardiovascular risk, further large-scale controlled trials are required before the efficacy and safety of GH treatment of adults can be established.


  • Why did the 5th Earl of Derby die?

    by William Jeffcoate


  • Diabète des femmes à barbe: a classic paper reread

    by William Jeffcoate, Marie-France Kong


  • The Charcot foot

    by W. Jeffcoate, J. Lima, L. Nobrega

    Aims To review the clinical manifestations of the Charcot foot in diabetes mellitus, with particular reference to theories concerning aetiology. Methods Systematic review of the published literature, searching for the keywords ‘Charcot’, ‘foot and diabetes’ and ‘neuropathy’ on Medline, as well as by examination of the references in recent published reviews. Conclusions The Charcot foot of diabetes mellitus is a common problem, and yet is not widely recognized by non‐specialists. The failure of professionals to identify the condition in its early phases is probably largely responsible for the gross deformity which follows continued weight‐bearing. The condition is confined to those with severe peripheral neuropathy. It is thought to result from three factors: motor neuropathy leading to the development of abnormal forces within the foot, subsequent disorganization of the foot as a result of associated osteopenia and progressive destruction from continued weight‐bearing, enabled by reduced pain sensation. The cause of the osteopenia is not known, but it is associated with increased bone blood flow, which may be mainly the result of loss of sympathetic innervation. The importance of increased limb blood flow in the pathogenesis of the Charcot foot has been recognized for over a century. Paradoxically, the increased flow is associated with evidence of macrovascular disease, in that the prevalence of vascular calcification of pedal vessels approaches 90%. After an interval of many months, the condition tends to evolve: the increased blood flow lessens, the osteopenia is reduced and the disorganized bones become sclerotic. This tendency for the condition to evolve remains unexplained, since it would not be expected if the condition was caused solely by progressive denervation. As a result, it is suggested that another factor may be involved in the pathogenesis of the Charcot foot: an abnormal vasomotor reflex, analogous to reflex sympathetic dystrophy, occurring against a background of severe peripheral neuropathy. The resolution of the condition occurs because it is the reflex component of the hyperaemia which proves self‐limiting.


  • Open Access

    Assessment of Corticosteroid Replacement Therapy in Adults with Adrenal Insufficiency

    by William Jeffcoate

    Recent work has taught us that our conventional approach to corticosteroid replacement therapy requires review. Specifically, the doses of hydrocortisone we have used are probably too high for the majority, and should ideally be administered in three or more doses through the day. Nevertheless, there is not much hard evidence that excessive glucocorticoid replacement per se will lead to adverse effects such as osteoporosis, even though it may exacerbate any tendency in those who are predisposed to it for other reasons. As such, there is no compelling need for using determinations of either UFC excretion or of the serum cortisol profile in the routine management of patients on replacement therapy. Nevertheless, such measures may be considered in those thought to be at particular risk of osteoporosis, and in whom it is felt that special effort should be made to ensure that they are receiving the minimum dose possible. In such circumstances, a cortisol day curve is likely to be of more value than measurement of UFC.